GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GeoVax Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026
$0.23−0.01 (-4.53%)
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-869.3%−714.9 pts over 5 years
Net margin
-862.3%−700.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -37.1% | +212.5% | +6.4% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -452.8% | -74.0% | -483.8% | |
| Return on assets | -337.0% | -54.5% | -296.1% | |
| Current ratio | 1.47 | 12.63 | 2.74 | |
| Debt to equity | – | 0.00 | – | |
| Net debt to EBITDA | – | 3.53× | – | |
| Interest coverage | – | -19.6× | – | |
| Capex to revenue | – | 8.6% | 1.1% | |
| Diluted shares | 0M | 1M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
GeoVax Labs generated $101.55M from operations and spent $279.19K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$101.55M
Used
$279.19K
Capital expenditure$279.19K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-862.3%
×Asset turnover0.34×
×Equity multiplier1.63×
=Return on equity, FY2025-483.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -862.3% | 0.34× | 1.63× | -483.8% |
| FY2024 | -632.0% | 0.45× | 1.61× | -462.3% |
| FY2022 | -17198.3% | 0.00× | 1.39× | -90.6% |
| FY2021 | -4817.2% | 0.03× | 1.59× | -266.6% |
| FY2020 | -162.2% | 0.34× | 1.36× | -74.0% |
| FY2019 | -201.6% | 2.12× | -0.43× | 182.6% |
| FY2018 | -265.8% | 1.70× | -0.84× | 381.1% |
| FY2017 | -201.8% | 1.95× | -13.64× | 5379.2% |
| FY2016 | -394.7% | 0.85× | 1.34× | -452.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$21.46M
- Cash generatingOperating cash flow above zero-$21.47M
- Return on assets improvedROA up on the prior year-269.2% → -263.2%
- Earnings backed by cashOperating cash flow above net income-$21.47M vs -$21.46M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.55 → 2.74
- No dilutionShare count did not rise0M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.43 → 0.31